GleamWall
中文EN

EQ Equillium, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1746466 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.9%
TTM net income YoY39.5%
TTM EPS YoY39.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-20.1%
Net margin-19.6%
FCF margin-46.5%
EBITDA margin-19.8%

Returns

ROE-38.8%
ROA-21.2%
ROIC (approx.)-3,923.0%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.36x
Accruals ratio28.8%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$4.39M
R&D expense$2.49M$2.75M$2.99M$1.54M$1.30M$4.08M$5.92M$7.32M
SG&A expense$2.56M$2.41M$2.62M$2.43M$3.27M$2.15M$2.95M$1.77M
Operating income-$5.05M-$5.16M-$5.61M-$3.96M-$4.58M-$6.23M-$8.87M-$4.70M
Income tax———$0$0$0$0$361,000
Net income-$4.58M-$4.69M-$5.31M-$3.77M-$4.23M-$5.74M-$8.65M-$5.79M
EBITDA-$5.02M-$5.13M-$5.59M-$3.94M-$4.55M-$6.20M-$8.84M-$4.66M
EPS (basic)-0.04-0.04-0.06—-0.06-0.16-0.24—
EPS (diluted)-0.04-0.04-0.06—-0.06-0.16-0.24—
Weighted avg. shares (diluted)111.92M111.81M96.28M—65.32M35.72M35.59M—
Balance sheet
Cash & equivalents$53.32M$57.16M$61.32M$30.28M$33.12M$11.49M$14.50M$18.09M
Short-term investments————$0$0$0$4.49M
Receivables———————$0
Current assets$54.95M$57.98M$62.27M$31.04M$33.58M$11.95M$16.22M$24.98M
PP&E, net$164,000$188,000$214,000$164,000$174,000$201,000$233,000$262,000
Total assets$55.81M$58.67M$63.08M$31.89M$34.51M$12.40M$16.73M$25.60M
Current liabilities$2.82M$2.48M$3.35M$2.93M$3.09M$7.23M$6.00M$6.36M
Total liabilities$3.13M$2.65M$3.60M$3.29M$3.57M$7.34M$6.15M$6.54M
Shareholders' equity$52.68M$56.02M$59.49M$28.60M$30.94M$5.06M$10.58M$19.06M
Shares outstanding63.41M63.41M63.23M61.46M60.68M35.72M35.72M35.56M
Cash flow statement
Operating cash flow-$3.83M-$4.11M-$4.30M-$3.13M-$8.43M-$3.01M-$8.17M-$3.30M
Capital expenditure$0$71,000$3,000$44,000$0$0$4,000$4,000
Free cash flow-$3.83M-$4.18M-$4.30M-$3.18M-$8.43M-$3.01M-$8.17M-$3.30M
Investing cash flow$0-$71,000-$3,000-$32,000$0$0$4.50M$6.00M
Financing cash flow-$1,000$42,000$35.35M$283,000$30.07M-$16,000$91,000$73,000
Depreciation & amortization$24,000$26,000$24,000$23,000$28,000$32,000$33,000$35,000
Stock-based compensation$1.26M$1.09M$930,000$737,000$401,000$563,000$621,000$821,000

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.